
|Articles|January 17, 2022
Daily Medication Pearl: Besifloxacin (Besivance)
Author(s)Saro Arakelians, PharmD
Besifloxacin ophthalmic suspension (Besivance) is indicated for the treatment of bacterial conjunctivitis.
Advertisement
Medication Pearl of the Day: Besivance (besifloxacin)
Indication: Besifloxacin ophthalmic suspension (Besivance) 0.6% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis.
Insight:
- Dosing: Instill 1 drop in the affected eye(s) 3 times a day, 4 to 12 hours apart for 7 days.
- Dosage forms:Ophthalmic suspension besifloxacin 6 mg/mL.
- Adverse events: The most common adverse reaction reported in 2% of patients treated with Besivance was conjunctival redness.
- Mechanism of action: Besifloxacin is a fluoroquinolone antibacterial agent.
- Manufacturer: Bausch & Lomb Incorporated.
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Awards National Priority Voucher to Teclistamab Plus Daratumumab in Relapsed/Refractory Multiple Myeloma
2
US Measles Cases Climb, Raising Questions About Preparedness and Prevention
3
Afamitresgene autoleucel: The First T-Cell Receptor Therapy on the Market
4
FDA Approves Depemokimab as Add-On Maintenance Treatment in Severe Asthma
5












































































































































































































